Social Media Press Releases

RSS

Showing Press Releases in Category: Business Development / Ventures

4/04/2011

MEDIMMUNE, INSERM AND INSERM TRANSFERT ANNOUNCE STRATEGIC COLLABORATION TO FUND AND CONDUCT MEDICAL SCIENCE RESEARCH

» read more
1/12/2011

MEDIMMUNE AND MICROMET ANNOUNCE INITIATION OF PHASE 1 TRIAL OF THE CEA BITE ANTIBODY MEDI-565 (MT111) IN PATIENTS WITH ADVANCED GASTROINTESTINAL CANCERS

» read more
1/07/2011

MEDIMMUNE IN-LICENSES CLINICAL-STAGE ANTI-INFLAMMATORY MONOCLONAL ANTIBODY FROM AMGEN

» read more
4/26/2010

MEDIMMUNE PRESENTS “A DIAMOND IN THE ROUGH – TRENDS AND STRATEGIES IN THE HEALTHCARE VC MARKET” AT 2010 BIO INTERNATIONAL CONVENTION IN CHICAGO

» read more
1/07/2008

MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas

» read more
6/18/2007

MedImmune, Inc. Announces Make-Whole Fundamental Change Relating to its 1.375% Convertible Senior Notes Due 2011 and 1.625% Convertible Senior Notes Due 2013

» read more
5/02/2007

MedImmune, Inc. Announces Convertibility of 1.375% Convertible Senior Notes Due 2011 and 1.625% Convertible Senior Notes Due 2013

» read more
4/23/2007

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.2 billion

» read more
4/12/2007

MedImmune Explores Strategic Alternatives

» read more
10/17/2005

MedImmune Completes Cellective Acquisition

» read more
9/14/2005

MedImmune to Acquire Cellective Therapeutics, Inc.

» read more
2/22/2005

MedImmune Allocates an Additional $100 Million to Venture Capital Fund

» read more